Anidulafungin and Micafungin Concentrations in Cerebrospinal Fluid and in Cerebral Cortex

被引:5
作者
Marx, Jana [1 ]
Welte, Rene [1 ]
Gasperetti, Tiziana [1 ]
Moser, Patrizia [2 ,9 ]
Beer, Ronny [3 ]
Ortler, Martin [4 ,10 ]
Jeske, Martina [5 ]
Stern, Ramona [5 ]
Pomaroli, Andreas [6 ,7 ]
Joannidis, Michael [8 ]
Bellmann, Romuald [1 ]
机构
[1] Med Univ Innsbruck, Dept Internal Med 1, Div Intens Care & Emergency Med, Clin Pharmacokinet Unit, Innsbruck, Austria
[2] Med Univ Innsbruck, Dept Pathol, Innsbruck, Austria
[3] Med Univ Innsbruck, Dept Neurol, Neurol ICU, Innsbruck, Austria
[4] Med Univ Innsbruck, Dept Neurosurg, Neurosurg ICU, Innsbruck, Austria
[5] Innsbruck Gen Hosp, Hosp Pharm, Innsbruck, Austria
[6] Innsbruck Gen Hosp, Ctr Operat Med, Dept Anesthesia & Crit Care, Transplant ICU, Innsbruck, Austria
[7] Med Univ Innsbruck, Innsbruck, Austria
[8] Med Univ Innsbruck, Dept Internal Med 1, Div Intens Care & Emergency Med, Innsbruck, Austria
[9] Tirol Kliniken, Dept Pathol, Innsbruck, Austria
[10] Krankenanstalt Rudolfstiftung Wien, Dept Neurosurg, Vienna, Austria
基金
奥地利科学基金会;
关键词
echinocandins; antifungal target-site pharmacokinetics; CNS penetration; fungal meningoencephalitis; CNS candidiasis; critically ill; TISSUE DISTRIBUTION; PHARMACOKINETICS; ECHINOCANDIN; PENETRATION; CASPOFUNGIN;
D O I
10.1128/AAC.00275-20
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Anidulafungin and micafungin were quantified in cerebrospinal fluid (CSF) of critically ill adults and in cerebral cortex of deceased patients. In CSF, anidulafungin levels (<0.01 to 0.66 mu g/ml) and micafungin levels (<0.01 to 0.16 mu g/ml) were lower than those in plasma concentrations (0.77 to 5.07 and 1.21 to 8.70 mu g/ml, respectively) drawn simultaneously. In cerebral cortex, anidulafungin and micafungin levels were 0.21 to 2.34 and 0.18 to 2.88 mu g/g, respectively. Thus, MIC values of several pathogenic Candida strains exceed concentrations in CSF and in brain.
引用
收藏
页数:5
相关论文
共 20 条
  • [1] In Vivo Comparison of the Pharmacodynamic Targets for Echinocandin Drugs against Candida Species
    Andes, D.
    Diekema, D. J.
    Pfaller, M. A.
    Bohrmuller, J.
    Marchillo, K.
    Lepak, A.
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2010, 54 (06) : 2497 - 2506
  • [2] High-Dose Micafungin for Preterm Neonates and Infants with Invasive and Central Nervous System Candidiasis
    Auriti, Cinzia
    Falcone, Marco
    Ronchetti, Maria Paola
    Goffredo, Bianca Maria
    Cairoli, Sara
    Crisafulli, Rosamaria
    Piersigilli, Fiammetta
    Corsetti, Tiziana
    Dotta, Andrea
    Pai, Manjunath P.
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2016, 60 (12) : 7333 - 7339
  • [3] ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients
    Cornely, O. A.
    Bassetti, M.
    Calandra, T.
    Garbino, J.
    Kullberg, B. J.
    Lortholary, O.
    Meersseman, W.
    Akova, M.
    Arendrup, M. C.
    Arikan-Akdagli, S.
    Bille, J.
    Castagnola, E.
    Cuenca-Estrella, M.
    Donnelly, J. P.
    Groll, A. H.
    Herbrecht, R.
    Hope, W. W.
    Jensen, H. E.
    Lass-Floerl, C.
    Petrikkos, G.
    Richardson, M. D.
    Roilides, E.
    Verweij, P. E.
    Viscoli, C.
    Ullmann, A. J.
    [J]. CLINICAL MICROBIOLOGY AND INFECTION, 2012, 18 : 19 - 37
  • [4] In vitro activity of micafungin (FK-463) against Candida spp.:: Microdilution, time-kill, and postantifungal-effect studies
    Ernst, EJ
    Roling, EE
    Petzold, CR
    Keele, DJ
    Klepser, ME
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (12) : 3846 - 3853
  • [5] Neuroinfections caused by fungi
    Goralska, Katarzyna
    Blaszkowska, Joanna
    Dzikowiec, Magdalena
    [J]. INFECTION, 2018, 46 (04) : 443 - 459
  • [6] Compartmental pharmacokinetics and tissue distribution of the antifungal echinocandin lipopeptide micafungin (FK463) in rabbits
    Groll, AH
    Mickiene, D
    Petraitis, V
    Petraitiene, R
    Ibrahim, KH
    Piscitelli, SC
    Bekersky, I
    Walsh, TJ
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (12) : 3322 - 3327
  • [7] Pharmacokinetic and pharmacodynamic modeling of anidulafungin (LY303366): Reappraisal of its efficacy in neutropenic animal models of opportunistic mycoses using optimal plasma sampling
    Groll, AH
    Mickiene, D
    Petraitiene, R
    Petraitis, V
    Lyman, CA
    Bacher, JS
    Piscitelli, SC
    Walsh, TJ
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (10) : 2845 - 2855
  • [8] Treatment of meningeal coccidioidomycosis with caspofungin
    Hsue, G
    Napier, JT
    Prince, RA
    Chi, J
    Hospenthal, DR
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2004, 54 (01) : 292 - 294
  • [9] Micafungin Concentrations from Brain Tissue and Pancreatic Pseudocyst Fluid
    Lat, Asma
    Thompson, George R., III
    Rinaldi, Michael G.
    Dorsey, Sheryl A.
    Pennick, Gennethel
    Lewis, James S., II
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2010, 54 (02) : 943 - 944
  • [10] Penetration of Drugs through the Blood-Cerebrospinal Fluid/Blood-Brain Barrier for Treatment of Central Nervous System Infections
    Nau, Roland
    Soergel, Fritz
    Eiffert, Helmut
    [J]. CLINICAL MICROBIOLOGY REVIEWS, 2010, 23 (04) : 858 - +